바카라 온라인 Biologics to attend ‘Interphex Week Tokyo 2025’ biotech and pharmaceutical convention
- 바카라 온라인 Biologics participates in ‘Solo Booth’ for the 2nd consecutive year, actively expanding order targets to top 40 global pharmaceutical firms beyond the Top 20 - To present ADC CDMO capabilities with dedicated production facilities and ‘end-to-end’ services to boost competitiveness - Strengthening global order activities, targeting customer expansion at BIO JAPAN and CPHI in October
[by Kang, In Hyo] 바카라 온라인 Biologics announced on July 8 that it will participate in ‘Interphex Week Tokyo 2025,’ a comprehensive biopharmaceutical convention taking place in Tokyo, Japan, from July 9 to 11.
Interphex Week Tokyo 2025 is Asia’s largest B2B convention, organized by the global exhibition company Reed Exhibitions (RX). It is recognized as an event dedicated to offering a discussion space for 바카라 온라인pharmaceutical manufacturing and R&D technology partnerships. Now in its 27th year, the convention is expected to host 900 companies from 25 countries and draw more than 34,000 attendees.
As in the previous year, 바카라 온라인 Biologics plans to operate a dedicated exhibition booth, aiming to actively engage with both existing and potential new clients. In particular, the company intends to leverage the event to accelerate the acquisition of new customers among the world’s top 40 pharmaceutical firms. 바카라 온라인 Biologics is also accelerating its expansion into the Asian market, having established a sales office in Tokyo, Japan, earlier this year, following the opening of its U.S. office.
Additionally, on the first day of the event, Marc Studer, Head of the ADC/mRNA Operations Team at 바카라 온라인 Biologics, will deliver a speaking session on the topic of ‘Navigating ADC Complexity: Ensuring safety, quality, and speed through a strategic CDMO Partnership.’ The session will highlight the company’s competitive strengths in the contract development and manufacturing (CDMO) of antibody drug conjugates (ADCs).
바카라 온라인 Biologics officially entered the ADC CDMO business in earnest with the launch of its dedicated ADC production facility in March. The company has established infrastructure for manufacturing ADC drug substances (DS), including a 500ℓ conjugation reactor and a purification line. Looking ahead, 바카라 온라인 Biologics plans to expand its capabilities to provide ‘end-to-end’ ADC CDMO services by installing a finished drug product (DP) manufacturing facility by 2027.
Conversely, 바카라 온라인 Biologics is actively reinforcing its order acquisition efforts through participation in major global industry events throughout the year. The company engaged with a wide range of clients at the JP Morgan Healthcare Conference (JPMHC) in January and at DCAT Week in March. It also took part in the BIO International Convention (BIO USA) held in Boston last month, where it showcased its strong competitiveness in securing global orders. 바카라 온라인 Biologics plans to further expand its outreach to current and prospective clients at BIO JAPAN 2025 and CPHI Worldwide in October.